Tigermed vs WuXi AppTec
WuXi AppTec holds the stronger position because its revenue, profit, and backlog are all climbing sharply while Tigermed's profit has collapsed under the same US-China pressure.
Tigermed
Chinese CRO running clinical trials for drugmakers, ranked among the world's largest
WuXi AppTec
Chinese CRO/CDMO running discovery-to-manufacturing services for global pharma clients
Dimension by dimension
| Dimension | Tigermed | WuXi AppTec |
|---|---|---|
| Staying power of the core product | Net new bookings rose 20.6% in 2025, but that order growth did not stop a 70% drop in quarterly profit. | Backlog grew 28.8% to RMB 58 billion, and that pipeline is translating into actual revenue and profit gains. |
| Exposure to AI absorbing the product | Running physical clinical trials and site operations is unlikely to be replaced by AI directly. | Discovery-to-manufacturing services also require physical lab and plant work that AI cannot substitute for. |
| How easily a giant could copy them | A large competitor could plausibly build a similar trial-running operation given enough capital and staff. | The integrated discovery-to-manufacturing setup is described as blocked from easy replication by a giant. |
| Pressure from rivals | IQVIA already leads China trial volume ahead of Tigermed, and US-China decoupling weighs on overseas growth. | Samsung Biologics is positioned to take US pharma volume WuXi cannot legally keep after BIOSECURE deadlines, but growth has continued despite it. |
| Financial footing | FY2025 revenue was RMB 6.83 billion, and Q1 2026 net profit fell 70.36% year over year. | FY2025 revenue reached RMB 45.46 billion, up 21.4%, with adjusted net profit up 41.3% to RMB 14.96 billion. |
| Recent profit trend | Profit is moving sharply in the wrong direction even as new bookings grow. | Profit is moving sharply in the right direction alongside revenue and backlog growth. |
Questions people ask
- Which company has stronger revenue growth, Tigermed or WuXi AppTec?
- WuXi AppTec's FY2025 revenue grew 21.4% to RMB 45.46 billion, far outpacing Tigermed's RMB 6.83 billion. Tigermed's growth in bookings did not prevent a 70.36% drop in Q1 2026 net profit, while WuXi's adjusted net profit rose 41.3%.
- Is Tigermed or WuXi AppTec more exposed to AI replacing their business?
- Both are rated unlikely to be absorbed by AI, since running clinical trials and running lab-to-manufacturing operations both depend on physical work AI cannot do directly. Neither company is described as more exposed than the other on this point.
- Could a big company copy Tigermed or WuXi AppTec's business easily?
- Tigermed's trial-running model is described as possible for a giant to copy with enough investment. WuXi AppTec's integrated discovery-to-manufacturing setup is described as blocked from easy copying, giving it more protection here.
- Who faces more competitive pressure, Tigermed or WuXi AppTec?
- Tigermed faces IQVIA, which already leads China trial volume, plus US-China decoupling headwinds overseas. WuXi AppTec faces Samsung Biologics, positioned to capture US pharma volume it cannot legally retain after BIOSECURE-related deadlines, yet WuXi's growth numbers have held up better so far.
- Which company has the bigger order pipeline, Tigermed or WuXi AppTec?
- WuXi AppTec's backlog grew 28.8% to RMB 58 billion in 2025. Tigermed's net new bookings grew 20.6% to RMB 10,158 million, a smaller base with growth that has not carried through to profit.
Other comparisons with these companies